ECONOMIC VALUE OF TREATING AND REDUCING THE BURDEN OF ATOPIC DERMATITIS AND COMORBID ASTHMA IN PAEDIATRIC PATIENTS USING DUPILUMAB: A DUTCH SOCIETAL COST-CONSEQUENCE ANALYSIS
Author(s)
Stefano Giavarini, MSc1, Marie Fournier, MSc2, Andreas Kuznik, PhD3, Chien-Chia Chuang, PhD4, Gaelle Bego Le Bagousse, MSc2, Zhixiao Wang, PhD3, Donia Bahloul, PharmD, MSc2.
1Sanofi, Amsterdam, Netherlands, 2Sanofi, Gentilly, France, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 4Sanofi, Cambridge, MA, USA.
1Sanofi, Amsterdam, Netherlands, 2Sanofi, Gentilly, France, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 4Sanofi, Cambridge, MA, USA.
OBJECTIVES: Dupilumab, a biologic approved for multiple type 2 inflammation-mediated indications, has been associated with reduced progression of the atopic march, including asthma, in paediatric patients with atopic dermatitis (AD). This analysis evaluated the potential societal implications of dupilumab versus conventional topical/systemic treatments (best supportive care [BSC]) in paediatric AD patients including its impact on comorbid asthma outcomes.
METHODS: A 5-year cost-consequence model was developed for children aged 6-11 years with moderate-to-severe AD (N = 16,650), with asthma or at risk of developing asthma, from a Dutch societal perspective. Epidemiological assumptions were informed by Chuang et al. (2025), with efficacy inputs from LIBERTY AD PEDS and LIBERTY Asthma VOYAGE trials. The potential impact of dupilumab on asthma incidence was modelled based on Lin et al. (2024) and extrapolated using a Weibull distribution. Cost categories (€, 2025) included drug acquisition, administration, AD management, asthma-related (prevalent and incident), and indirect costs. Education costs were used as a proxy for productivity losses in paediatric patients. Outcomes included healthcare resource utilisation (HCRU), asthma incidence, productivity losses, and healthcare provider time.
RESULTS: Dupilumab was associated with reduced net societal cost over five years compared with BSC (€1,204.0M vs €1,225.2M; savings: €21.1M), driven primarily by reductions in indirect costs (€435.0M), AD management costs (€68.0M), and asthma-related costs (€6.1M). Compared with BSC, dupilumab demonstrated a 28.0% reduction in total HCRU and a 22.0% reduction in asthma incidence. Dupilumab treatment was associated with a 21.0% reduction in cumulative healthcare provider time. Over 5 years, a 41.0% decrease in productivity losses was observed across patients and caregivers.
CONCLUSIONS: Dupilumab showed lower societal cost and health outcomes, not only from improvement in AD, but also related to prevalent and incident asthma compared with BSC for paediatric patients with AD.
METHODS: A 5-year cost-consequence model was developed for children aged 6-11 years with moderate-to-severe AD (N = 16,650), with asthma or at risk of developing asthma, from a Dutch societal perspective. Epidemiological assumptions were informed by Chuang et al. (2025), with efficacy inputs from LIBERTY AD PEDS and LIBERTY Asthma VOYAGE trials. The potential impact of dupilumab on asthma incidence was modelled based on Lin et al. (2024) and extrapolated using a Weibull distribution. Cost categories (€, 2025) included drug acquisition, administration, AD management, asthma-related (prevalent and incident), and indirect costs. Education costs were used as a proxy for productivity losses in paediatric patients. Outcomes included healthcare resource utilisation (HCRU), asthma incidence, productivity losses, and healthcare provider time.
RESULTS: Dupilumab was associated with reduced net societal cost over five years compared with BSC (€1,204.0M vs €1,225.2M; savings: €21.1M), driven primarily by reductions in indirect costs (€435.0M), AD management costs (€68.0M), and asthma-related costs (€6.1M). Compared with BSC, dupilumab demonstrated a 28.0% reduction in total HCRU and a 22.0% reduction in asthma incidence. Dupilumab treatment was associated with a 21.0% reduction in cumulative healthcare provider time. Over 5 years, a 41.0% decrease in productivity losses was observed across patients and caregivers.
CONCLUSIONS: Dupilumab showed lower societal cost and health outcomes, not only from improvement in AD, but also related to prevalent and incident asthma compared with BSC for paediatric patients with AD.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE120
Topic
Economic Evaluation, Health Technology Assessment
Disease
Biologics & Biosimilars, Pediatrics, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Sensory System Disorders (Ear, Eye, Dental, Skin)